NCT07483476 2026-03-19
CIRCALL
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Clinical Trials
15 trialsNCT07454486 2026-03-06
TRACE-BTC
Aarhus University Hospital
Not yet recruiting
NCT07443592 2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA Not yet recruiting
NCT07413146 2026-02-17
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
Phase NA Not yet recruiting
NCT07392970 2026-02-06
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07382505 2026-02-02
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
Asan Medical Center
Not yet recruiting
NCT07350824 2026-01-20
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Tongji Hospital
Phase NA Not yet recruiting
NCT07112612 2026-01-12
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
Anhui Medical University
Not yet recruiting
NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07247201 2025-12-09
AlloNK1
Singapore General Hospital
Phase 1/2 Not yet recruiting
NCT07269067 2025-12-08
DUALFLOW
University Hospital, Bordeaux
Not yet recruiting
NCT07264010 2025-12-04
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT07257380 2025-12-02
MRD-ATLAS
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07045168 2025-09-15
Risk-adapted Therapeutic Strategy in +1q NDMM
The First Hospital of Jilin University
Not yet recruiting
NCT06941987 2025-04-24
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Shanghai Zhongshan Hospital
Not yet recruiting